Pancreatic Cancer Research

ResearcherGuangdong Academy of Medical SciencesActive in the last 2 years

Yu Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5999-7966; OpenAlex author ID A5079124782. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 7

  1. Lactylation-driven NSUN2-mediated RNA m5C modification promotes perineural invasion in pancreatic cancer. Co-author DOI 10.7150/thno.122294↗
  2. N4-acetylcytidine modification of ITGB5 mRNA mediated by NAT10 promotes perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-025-03362-2↗
  3. RBMS1-mediates the biogenesis of circNFIB promotes perineural invasion of pancreatic ductal adenocarcinoma via the L1CAM/MAPK pathway. Co-author DOI 10.7150/thno.112753↗
  4. Nudt21-mediated alternative polyadenylation of MZT1 3'UTR contributes to pancreatic cancer progression. Co-author DOI 10.1016/j.isci.2024.108822↗
  5. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer. Co-author DOI 10.1186/s13046-023-02854-3↗
  6. Down-regulated lncRNA SBF2-AS1 in M2 macrophage-derived exosomes elevates miR-122-5p to restrict XIAP, thereby limiting pancreatic cancer development. First author DOI 10.1111/jcmm.15125↗
  7. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway. Co-author DOI 10.1186/s13046-019-1313-x↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rihua He · 3 shared papers, 2023–2026 · strength 0.64
  2. Rufu Chen · 2 shared papers, 2024–2025 · strength 0.54
  3. Leyi Huang · 2 shared papers, 2024–2025 · strength 0.48
  4. Quanbo Zhou · 2 shared papers, 2024–2025 · strength 0.48
  5. Chonghui Hu · 2 shared papers, 2023–2026 · strength 0.41
  6. Shangyou Zheng · 2 shared papers, 2023–2026 · strength 0.41
  7. Zhiqiang Fu · 2 shared papers, 2023–2025 · strength 0.40
  8. Liangtang Zeng · 1 shared paper, 2025 · strength 0.30
  9. Zhuo Kui Wu · 1 shared paper, 2025 · strength 0.30
  10. Dingwen Zhang · 1 shared paper, 2025 · strength 0.30
  11. Tianhao Huang · 1 shared paper, 2026 · strength 0.24
  12. Zhihua Li · 1 shared paper, 2026 · strength 0.24
  13. Huimou Chen · 1 shared paper, 2026 · strength 0.24
  14. Rufu Chen · 1 shared paper, 2026 · strength 0.24
  15. Jiabin Yang · 1 shared paper, 2024 · strength 0.24
  16. Rufu Chen · 1 shared paper, 2025 · strength 0.24
  17. Zi Yin · 2 shared papers, 2019–2020 · strength 0.22
  18. Yiping Zou · 2 shared papers, 2019–2020 · strength 0.22
  19. Sheng Chen · 2 shared papers, 2019–2020 · strength 0.22
  20. Rufu Chen · 1 shared paper, 2023 · strength 0.16
  21. Shuxin Sun · 1 shared paper, 2023 · strength 0.16
  22. Yuming Luo · 1 shared paper, 2023 · strength 0.16
  23. Renpeng Xia · 1 shared paper, 2023 · strength 0.16
  24. Ning Shi · 1 shared paper, 2020 · strength 0.12
  25. Chuanzhao Zhang · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.